Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance
‘Our Focus Is On Driving Long-Term EBITDA Growth,’ Endo Insists
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.
You may also be interested in...
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Endo’s Par has announced the first launch under a longstanding US collaboration with 505(b)(2) specialist Nevakar, in the form of pre-mixed ephedrine sulfate injection in a ready-to-use 50mg/10ml single-use vial.
Hot on the heels of Eagle’s first US generic launch, Dr Reddy’s has launched an authorized generic version of vasopressin at the same time as Endo’s Par Sterile Products has also launched a new pre-mixed ready-to-use presentation of the Vasostrict brand. Meanwhile, American Regent has also launched its 505(b)(2) product referencing Vasostrict.